UniProtKB/Swiss-Prot P60484 : Variant p.Cys124Ser
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Gene: PTEN
Feedback ?
Variant information
Variant position:
124
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Cysteine (C) to Serine (S) at position 124 (C124S, p.Cys124Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and polar (C) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In CWS1; phosphatase-dead protein with neither lipid nor protein phosphatase activity.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
124
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
403
The length of the canonical sequence.
Location on the sequence:
FCEDLDQWLSEDDNHVAAIH
C KAGKGRTGVMICAYLLHRGK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human FCEDLDQWLSEDDNHVAAIHC KAGKGRTGVMICAYLLHRGK
FCEDLDQWLSEDDNHVAAIHC KAGKGRTGVMICAYLLHRGK
Mouse FCEDLDQWLSEDDNHVAAIHC KAGKGRTGVMICAYLLHRGK
Rat FCEDLDQWLSEDDNHVAAIHC KAGKGRTGVMICAYLLHRGK
Xenopus laevis FCEDLDQLLSENEN-VAAIHC KAGKGRTGVMICAYLLHRGK
Caenorhabditis elegans FCREAKEWLEADDKHVIAVHC KAGKGRTGVMICALLIYINF
Slime mold FCRDVDAWMKEDSKNIAVIHC KAGKGRTGLMICCWLMYCGM
Fission yeast IVMNMDALFQTQPLLTLVVHC KAGKGRTGTVICSYLVAFGG
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 403
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Domain
14 – 185
Phosphatase tensin-type
Active site
124 – 124
Phosphocysteine intermediate
Mutagenesis
124 – 124
C -> A. Loss of protein phosphatase activity. Unable to inhibit focal adhesion formation.
Mutagenesis
124 – 124
C -> S. Loss of phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity.
Mutagenesis
125 – 125
K -> M. Reduced phosphatase activity towards PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P.
Mutagenesis
126 – 126
A -> P. Does not reduce phosphatase activity towards PtdIns(3,4,5)P3 and PtdIns(3,4)P2.
Mutagenesis
126 – 126
A -> S. Does not reduce phosphatase activity towards PtdIns(3,4,5)P3 and PtdIns(3,4)P2.
Mutagenesis
126 – 126
A -> V. Does not reduce phosphatase activity towards PtdIns(3,4,5)P3 and PtdIns(3,4)P2.
Mutagenesis
128 – 128
K -> M. 85% reduction in phosphatase activity towards PtdIns(3,4,5)P3.
Mutagenesis
128 – 128
K -> R. Does not reduce phosphatase activity towards PtdIns(3,4,5)P3.
Mutagenesis
130 – 130
R -> M. Does not affect the ability to inhibit AKT/PKB activation.
Literature citations
The lipid phosphatase activity of PTEN is critical for its tumor suppressor function.
Myers M.P.; Pass I.; Batty I.H.; Van der Kaay J.; Stolarov J.P.; Hemmings B.A.; Wigler M.H.; Downes C.P.; Tonks N.K.;
Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998)
Cited for: FUNCTION; CATALYTIC ACTIVITY; MUTAGENESIS OF ARG-130; CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129;
PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.
Weng L.-P.; Brown J.L.; Eng C.;
Hum. Mol. Genet. 10:599-604(2001)
Cited for: CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.